RB1 and ovarian carcinoma: A decrease in important elements in this pathway, like P-PI3K, P-AKT, CCND1, CDK4, and P-RB, supports the idea that Kirenol could potentially inhibit this signaling cascade, providing new understanding of how it works and strengthening its potential as a hopeful treatment for ovarian cancer.